Treatment of lower respiratory tract infections (pneumonia, bronchitis), genitourinary infections (prostatitis, UTIs) caused by E. coli, K. pneumoniae, C. trachomatis, N. gonorrhoeae; skin and skin-structure infections
Rapidly and well absorbed from the GI tract. Protein binding: 20%–25%. Widely distributed (including to CSF). Metabolized in the liver. Primarily excreted in urine. Removed by hemodialysis. Half-life: 4.7–7 hr (increased in impaired renal function, cirrhosis, and the elderly).
Well absorbed after PO administration. Protein binding: 93%. Extensively distributed throughout the body. Undergoes extensive first-pass metabolism in the liver. Excreted primarily in urine and, to a lesser extent, in feces. Not removed by dialysis. Half-life: 21–54 hr.
Lactation, paralytic ileus, elderly; combination of age, smoking, and gender (female) may increase clearance rate; neuroleptic malignant syndrome, cardiovascular disease, cerebrovascular disease, seizures, orthostatic hypotension, Alzheimer’s dementia, prostate hypertrophy, glaucoma; patients should be monitored for signs and symptoms of diabetes mellitus
! Rare reactions include seizures and neuroleptic malignant syndrome, a potentially fatal syndrome characterized by hyperpyrexia, muscle rigidity, irregular pulse or B/P, tachycardia, diaphoresis, and cardiac arrhythmias.
• Physician should be informed if significant xerostomic side effects occur (e.g., increased caries, sore tongue, problems eating or swallowing, difficulty wearing prosthesis) so that a medication change can be considered.
Rapidly, completely absorbed after PO administration. Protein binding: 99%. Olmesartan medoxomil is an inactive drug. It is hydrolyzed in the gastrointestinal tract to active olmesartan, which is absorbed. Bioavailability: 26%. Food does not affect the bioavailability of olmesartan. Dose not cross blood-brain barrier. Primarily excreted in feces and to a lesser extent in urine. Half-life: 13 hr.
Pregnancy: [U.S. Boxed Warning]: “Based on human data, drugs that act on the angiotensin system can cause injury and death to the developing fetus when used in the second and third trimesters. Angiotensin receptor blockers should be discontinued as soon as possible once pregnancy is detected.”
Reduction of asthma exacerbation in patients with moderate to severe asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen not adequately controlled by inhaled glucocorticoids
A combination of ethyl esters of omega 3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) but the mechanism of action is not well understood. May inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, increase mitochondrial and peroxisomal β-oxidation in the liver, decrease lipogenesis in the liver, and increase plasma lipoprot/>